Study evaluating PK, PD, and safety of Cilofexor (CILO) and its inactive metabolites (GS- 716070 and GS-1056756) in Japanese and Caucasian participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 May 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cilofexor (Primary)
Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

07 May 2020 New trial record
21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com